Alisporivir (DEB025), a cyclosporin A derivative, is a new antiviral drug which targets host cell factors (cyclophilins) inhibiting viral replication without immunosuppressive effects. This drug potently inhibits cyclophilin-dependent HCV replication with an additive antiviral effect to standard-of-care (SoC) therapy for HCV. The administration of alisporivir in addition to SoC enhances activity against all HCV genotypes, with a good safety profile. Currently, two trials are ongoing: a Phase III and a Phase II trial assessing the efficacy of alisporivir plus SoC in genotype-1 treatment-naive patients and nonresponders or relapsers. Another Phase II study is examining the potential use of alisporivir for IFN-free treatment in HCV genotype 2 and 3 patients naive to treatment. In this review, we describe the unique characteristics of this cyclophilin inhibitor and benefit afforded by this drug in combination therapy with current and future HCV treatments.

Azzaroli F, Turco L, Lisotti A, Cecinato P, Calvanese C, Buonfiglioli F, et al. (2012). Alisporivir for the treatment of chronic HCV. FUTURE VIROLOGY, 7, 9-18 [10.2217/FVL.11.137].

Alisporivir for the treatment of chronic HCV

AZZAROLI, FRANCESCO;TURCO, LAURA;LISOTTI, ANDREA;CECINATO, PAOLO;BUONFIGLIOLI, FEDERICA;MONTAGNANI, MARCO;MAZZELLA, GIUSEPPE
2012

Abstract

Alisporivir (DEB025), a cyclosporin A derivative, is a new antiviral drug which targets host cell factors (cyclophilins) inhibiting viral replication without immunosuppressive effects. This drug potently inhibits cyclophilin-dependent HCV replication with an additive antiviral effect to standard-of-care (SoC) therapy for HCV. The administration of alisporivir in addition to SoC enhances activity against all HCV genotypes, with a good safety profile. Currently, two trials are ongoing: a Phase III and a Phase II trial assessing the efficacy of alisporivir plus SoC in genotype-1 treatment-naive patients and nonresponders or relapsers. Another Phase II study is examining the potential use of alisporivir for IFN-free treatment in HCV genotype 2 and 3 patients naive to treatment. In this review, we describe the unique characteristics of this cyclophilin inhibitor and benefit afforded by this drug in combination therapy with current and future HCV treatments.
2012
Azzaroli F, Turco L, Lisotti A, Cecinato P, Calvanese C, Buonfiglioli F, et al. (2012). Alisporivir for the treatment of chronic HCV. FUTURE VIROLOGY, 7, 9-18 [10.2217/FVL.11.137].
Azzaroli F; Turco L; Lisotti A; Cecinato P; Calvanese C; Buonfiglioli F; Cevenini M; Montagnani M; Mazzella G.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/112996
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact